GB1350114A - Anabolic treatment of domestic animals - Google Patents

Anabolic treatment of domestic animals

Info

Publication number
GB1350114A
GB1350114A GB4608971A GB4608971A GB1350114A GB 1350114 A GB1350114 A GB 1350114A GB 4608971 A GB4608971 A GB 4608971A GB 4608971 A GB4608971 A GB 4608971A GB 1350114 A GB1350114 A GB 1350114A
Authority
GB
United Kingdom
Prior art keywords
domestic animals
oct
anabolic treatment
animals
anabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4608971A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB1350114A publication Critical patent/GB1350114A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB4608971A 1970-10-06 1971-10-04 Anabolic treatment of domestic animals Expired GB1350114A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7863670A 1970-10-06 1970-10-06

Publications (1)

Publication Number Publication Date
GB1350114A true GB1350114A (en) 1974-04-18

Family

ID=22145320

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4608971A Expired GB1350114A (en) 1970-10-06 1971-10-04 Anabolic treatment of domestic animals

Country Status (6)

Country Link
US (1) US3670079A (https=)
AU (1) AU454533B2 (https=)
CA (1) CA968710A (https=)
DE (1) DE2149744A1 (https=)
FR (1) FR2110251B1 (https=)
GB (1) GB1350114A (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013762A (en) * 1976-05-10 1977-03-22 Richardson-Merrell Inc. Growth promotion
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
IL152771A0 (en) * 2000-06-26 2003-06-24 Pfizer Prod Inc PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254074A (en) * 1962-04-25 1966-05-31 Merck & Co Inc Spiroxenones

Also Published As

Publication number Publication date
FR2110251A1 (https=) 1972-06-02
US3670079A (en) 1972-06-13
AU454533B2 (en) 1974-10-31
AU3384971A (en) 1973-03-29
DE2149744A1 (de) 1972-04-13
FR2110251B1 (https=) 1975-06-06
CA968710A (en) 1975-06-03

Similar Documents

Publication Publication Date Title
GB1374823A (en) Triazolylbenzophenones
GB1331405A (en) Esters their production and their medicinal use
GB1350114A (en) Anabolic treatment of domestic animals
GB1154744A (en) Disubstituted Aminoethanols
GB1354571A (en) Amides and their use as insecticides
GB1188846A (en) Thiazole Derivatives
ES375203A1 (es) Un procedimiento para preparar un derivado de benzotiazepi-na.
GB1137764A (en) Improvements in or relating to pharmacologically-active secondary amines
GB1169945A (en) Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
SE7503080L (https=)
GB1291442A (en) Adamantylamino-5,8-dihydronaphthyloxy-propanols and related compounds
GB1362845A (en) Benzyl alcohol derivatives
GB1412932A (en) Pharmaceutically active leurosine derivatives and preparation thereof
GB1341339A (en) Pyridyl thiourea derivatives and preparation thereof
GB1169990A (en) Phenoxy Propan-2-Olamines
GB1333992A (en) Method of and compositions for combating mareks disease
GB1311618A (en) 4-sulphanilyl phenyl urea complexes
GB1170860A (en) Quinoline-3-Carboxylates
GB1173809A (en) N-Substituted Nor-Morphines
GB1203430A (en) Heterocyclic spiro compounds
GB1132397A (en) Improvements in or relating to fluorene derivatives and the manufacture thereof
GB1408109A (https=)
GB1364318A (en) Laurotetanine derivatives
GB1280551A (en) Quinazoline derivatives
GB1394126A (en) Fungicidally active 1,3,4-thiadiazole derivatives

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee